Rigel Pharmaceuticals

Activities: Ingredients Research & Development

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Rigel names Anne-Marie Duliege as Chief Medical Officer

Elliott Grossbard retires but will continue advising on NDA filing for fostamatinib
Research & Development

Rigel to concentrate on three of its leading clinical programmes

This will mean cutting its workforce by about 18% or 30 people
Regulatory

Autoimmune diseases – fostamatinib

Spleen tyrosine kinase, or SYK, has potential as a target in various autoimmune conditions, such as rheumatoid arthritis
Research & Development

Drug licensing deals in 2010

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Regulatory

AstraZeneca to pay Rigel up to US$1.25bn in arthritis agreement

AstraZeneca is to make an upfront payment of US$100m to Rigel Pharmaceuticals in an exclusive license agreement to develop fostamatinib disodium (R788), Rigel\'s late-stage investigational product for the treatment of rheumatoid arthritis (RA).
Subscribe now